Predictors of response to erenumab after 12 months of treatment

OBJECTIVE: Erenumab is a monoclonal antibody acting against calcitonin gene‐related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overus...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraldi, Carlo, Castro, Flavia Lo, Cainazzo, Maria Michela, Pani, Luca, Guerzoni, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413721/
https://www.ncbi.nlm.nih.gov/pubmed/34268907
http://dx.doi.org/10.1002/brb3.2260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413721/
https://www.ncbi.nlm.nih.gov/pubmed/34268907
http://dx.doi.org/10.1002/brb3.2260

Ejemplares similares